- Report
- January 2026
- 180 Pages
Global
From €3996EUR$4,500USD£3,427GBP
- Report
- August 2026
- 188 Pages
Global
From €3148EUR$3,545USD£2,700GBP
€3498EUR$3,939USD£3,000GBP
- Report
- November 2025
- 183 Pages
Global
From €3148EUR$3,545USD£2,700GBP
€3498EUR$3,939USD£3,000GBP
- Report
- February 2026
- 250 Pages
Global
From €3987EUR$4,490USD£3,419GBP
- Report
- February 2026
- 250 Pages
Global
From €3987EUR$4,490USD£3,419GBP
- Report
- May 2026
- 150 Pages
Global
From €5283EUR$5,950USD£4,531GBP
- Report
- May 2026
- 140 Pages
Global
From €2663EUR$2,999USD£2,284GBP
€3551EUR$3,999USD£3,045GBP
- Report
- August 2026
- 272 Pages
Global
From €5194EUR$5,850USD£4,455GBP
- Report
- August 2026
- 203 Pages
Global
From €5194EUR$5,850USD£4,455GBP
- Report
- August 2026
- 172 Pages
Global
From €5194EUR$5,850USD£4,455GBP
- Report
- August 2026
- 190 Pages
Global
From €3148EUR$3,545USD£2,700GBP
€3498EUR$3,939USD£3,000GBP
- Report
- August 2026
- 182 Pages
Global
From €3148EUR$3,545USD£2,700GBP
€3498EUR$3,939USD£3,000GBP
- Report
- January 2026
- 192 Pages
Global
From €3148EUR$3,545USD£2,700GBP
€3498EUR$3,939USD£3,000GBP
- Report
- November 2025
- 189 Pages
Global
From €3148EUR$3,545USD£2,700GBP
€3498EUR$3,939USD£3,000GBP
- Report
- February 2026
- 250 Pages
Global
From €3987EUR$4,490USD£3,419GBP
- Report
- May 2026
- 185 Pages
Global
From €3996EUR$4,500USD£3,427GBP
- Report
- January 2026
- 180 Pages
Global
From €3996EUR$4,500USD£3,427GBP
- Report
- January 2026
- 185 Pages
Global
From €3996EUR$4,500USD£3,427GBP
- Report
- January 2026
- 180 Pages
Global
From €3996EUR$4,500USD£3,427GBP
- Report
- March 2026
- 250 Pages
Global
From €3987EUR$4,490USD£3,419GBP

The Neurodegenerative Disease market is a subset of the Neurosciences field that focuses on the diagnosis, treatment, and prevention of diseases that cause the progressive loss of structure or function of neurons, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). These diseases are characterized by the gradual degeneration of the nervous system, leading to a decline in cognitive and motor functions. Treatment options for these diseases are limited, and there is currently no cure.
The Neurodegenerative Disease market is composed of a variety of companies, including pharmaceutical companies, biotechnology companies, medical device companies, and research organizations. Examples of companies in this market include AbbVie, Biogen, Novartis, Merck, and Pfizer. Show Less Read more